Novo Nordisk is lowering what Wegovy costs in China, a fresh move in the race for the country's obesity drug market. No figures were given.
Recap by typeshit. Full story at ΕΜΥ.
Hanmi set Eppe's first four weeks at 129,800 won ahead of a late-month launch, while Novo seeks Korean insurance coverage for Wegovy in high-risk patients.
Novo trades near 11.8 times forward earnings against an 18.6 average, and the piece asks whether that makes it a buying chance or a value trap.
About half of Australia's roughly 500,000 GLP-1 users pay privately, A$200 to $700 a month, and the authors argue cost hits those with the most obesity hardest.
Ireland's drug pricing body recommended semaglutide over tirzepatide for cost reasons, and Higgins says it's the right call, with a pun he didn't get to use.
A Facebook post credits Novo Nordisk's GLP-1 drugs with strong results in obesity and type 2 diabetes, plus lower risk of other conditions.
Lilly's tirzepatide shot Zepbound now has FDA approval in a KwikPen format for weight management. Tap through for details on the new pen.
Loading…